期刊文献+

端粒酶活性调控研究进展 被引量:3

下载PDF
导出
出处 《实用临床医药杂志》 CAS 2010年第3期25-31,共7页 Journal of Clinical Medicine in Practice
基金 国家自然科学基金资助项目(30871150 30900679) 重庆市杰出青年科学基金资助项目(CSTC 2009BA5045)
  • 相关文献

参考文献8

二级参考文献32

  • 1Aili Li,Long Mao.Evolution of plant microRNA gene families[J].Cell Research,2007,17(3):212-218. 被引量:14
  • 2Feng J L,Science,1995年,269卷,1236页
  • 3Feng J,Science,1995年,269卷,1236页
  • 4Zhang X L,Gene & Development,1999年,13卷,18期,2388页
  • 5Nguyen DC, Crowe DL. Intact functional domains of the retinoblastoma gene product (pRb) are required for downregulation of telomerase activity. Biochim Biophys Acta, 1999, 1445: 207-215.
  • 6Hanahan D, Weinberg RA . The hallmarks of cancer. Cell, 2000, 100: 57-70.
  • 7Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev, 1998,12:2245-2262.
  • 8Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. J Biol Chem, 2002, 277: 11617-11620.
  • 9Landberg G, Nielsen NH, Nilsson P, et al. Telomerase activity is associated with cell cycle deregulation in human breast cancer. Cancer Res, 1997, 57: 549-554.
  • 10Crowe DL, Nguyen DC. Rb and E2F-1 regulate telomerase activity in human cancer cells. Biochim Biophys Acta, 2001, 1518: 1-6.

共引文献63

同被引文献32

  • 1陈陵,杨仕明,蔡永国,房殿春,李晶晶,罗元辉.针对端粒酶蛋白催化亚单位的肿瘤免疫治疗研究[J].世界华人消化杂志,2005,13(4):528-533. 被引量:16
  • 2陈陵,向国春,李向红,蔡永国,李晶晶,房殿春,罗元辉,李志宏,杨仕明.负载hTERT复制缺陷型腺病毒的包装及鉴定[J].第四军医大学学报,2006,27(1):53-56. 被引量:7
  • 3毛立军,郑骏年,郑宏祥,孙晓青,陈家存,刘俊杰.转录hTERT基因shRNA的溶瘤腺病毒的构建及抗肿瘤效应[J].实用肿瘤杂志,2007,22(1):12-17. 被引量:2
  • 4李永明 赵玉琪.实用分子生物学方法手册[M].北京:科学出版社,1999.366.
  • 5Bertorelle R, Briarava M, Rampazzo E, et al. Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer[ J]. Br J Cancer,2013,108 (2) :278 -284.
  • 6Chen L,Tang XD, Yu ST, et al. Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice [ J ]. J Pathol, 2009,217 (5) :685 -692.
  • 7Stamatopoulos B, Meuleman N, Haibe-Kains B, et al.mieroRNA-29c and mieroRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification [ J 1. Blood, 2009,113 (21) :5237 - 5245.
  • 8Wang W,Zhao LJ, Tan YX, et al. MiR-138 induces cell cycle arrest by targeting eyclin D3 in hepatocellular carcinoma[ J ]. Carcinogenesis, 2012,33 ( 5 ) : 1113 - 1120.
  • 9Song T, Zhang X, Wang C, et al. MiR-138 suppresses expression of hypoxia-inducible factor l alpha (HIF- lalpha) in clear cell renal cell carcinoma 786-0 cells [ J ]. Asian Pac J Cancer Prev, 2011,12 ( 5 ) : 1307 - 1311.
  • 10Xu C, Fu H, Gao L, et al. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia I J ]. Oncogene, 2012: doi: 10. I038/onc. 2012. 557.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部